The GLUTs family - Lessons from transgenic mice

K. Hartil, R. H. Weldon, Y. Seki, Maureen J. Charron

Research output: Contribution to journalArticle

Abstract

The glucose transporters (GLUTs) are currently a 13 member family of facilitative transmembrane proteins which transport glucose down its concentration gradient. The GLUTs have a tissue specific expression and regulation. Dysregulation of GLUTs have been implicated in the pathogenesis of a number of diseases including diabetes and cancer and are known to play an important role in the developing embryo. In addition, roles for GLUTs in cardiac function and embryonic development have been identified and will be discussed in this review. The ability to ablate or over-express GLUTs has advanced our understanding of the role these transporters play in the maintenance of normal glucose homeostasis and the pathogenesis of diabetes. The development of Cre-LoxP technology coupled with the existence of tissue specific promoters allows investigators to manipulate gene expression both globally and in a tissue specific manner. The major GLUTs which have been investigated using transgenic technology are GLUT1, GLUT4 and GLUT2. Overexpression of GLUT4 and GLUT1 results in increased glucose uptake and metabolism. However, only GLUT4 overexpression protects against the development of insulin resistance in transgenic mice. Genetic ablation of GLUT4 and GLUT2 results in impaired insulin tolerance and defects in both lipid and glucose metabolism. This review will present various transgenic models of GLUT modification and discuss what has been learned from these models about the role that GLUTs play in glucose homeostasis, insulin action and development.

Original languageEnglish (US)
Pages (from-to)189-206
Number of pages18
JournalCurrent Medicinal Chemistry: Immunology, Endocrine and Metabolic Agents
Volume5
Issue number2
DOIs
StatePublished - Apr 2005

Fingerprint

Facilitative Glucose Transport Proteins
Transgenic Mice
Glucose
Homeostasis
Insulin
Technology
Aptitude
Protein Transport
Lipid Metabolism
Embryonic Development
Insulin Resistance
Embryonic Structures
Maintenance
Research Personnel
Gene Expression

Keywords

  • Cardiovascular
  • Development
  • Diabetes
  • GLUT
  • Hypertrophy
  • Insulin
  • Knockout
  • Transgenic

ASJC Scopus subject areas

  • Pharmacology
  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy

Cite this

The GLUTs family - Lessons from transgenic mice. / Hartil, K.; Weldon, R. H.; Seki, Y.; Charron, Maureen J.

In: Current Medicinal Chemistry: Immunology, Endocrine and Metabolic Agents, Vol. 5, No. 2, 04.2005, p. 189-206.

Research output: Contribution to journalArticle

@article{110644e6a7664830919c30622723d856,
title = "The GLUTs family - Lessons from transgenic mice",
abstract = "The glucose transporters (GLUTs) are currently a 13 member family of facilitative transmembrane proteins which transport glucose down its concentration gradient. The GLUTs have a tissue specific expression and regulation. Dysregulation of GLUTs have been implicated in the pathogenesis of a number of diseases including diabetes and cancer and are known to play an important role in the developing embryo. In addition, roles for GLUTs in cardiac function and embryonic development have been identified and will be discussed in this review. The ability to ablate or over-express GLUTs has advanced our understanding of the role these transporters play in the maintenance of normal glucose homeostasis and the pathogenesis of diabetes. The development of Cre-LoxP technology coupled with the existence of tissue specific promoters allows investigators to manipulate gene expression both globally and in a tissue specific manner. The major GLUTs which have been investigated using transgenic technology are GLUT1, GLUT4 and GLUT2. Overexpression of GLUT4 and GLUT1 results in increased glucose uptake and metabolism. However, only GLUT4 overexpression protects against the development of insulin resistance in transgenic mice. Genetic ablation of GLUT4 and GLUT2 results in impaired insulin tolerance and defects in both lipid and glucose metabolism. This review will present various transgenic models of GLUT modification and discuss what has been learned from these models about the role that GLUTs play in glucose homeostasis, insulin action and development.",
keywords = "Cardiovascular, Development, Diabetes, GLUT, Hypertrophy, Insulin, Knockout, Transgenic",
author = "K. Hartil and Weldon, {R. H.} and Y. Seki and Charron, {Maureen J.}",
year = "2005",
month = "4",
doi = "10.2174/1568013053586496",
language = "English (US)",
volume = "5",
pages = "189--206",
journal = "Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry",
issn = "1871-5222",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - The GLUTs family - Lessons from transgenic mice

AU - Hartil, K.

AU - Weldon, R. H.

AU - Seki, Y.

AU - Charron, Maureen J.

PY - 2005/4

Y1 - 2005/4

N2 - The glucose transporters (GLUTs) are currently a 13 member family of facilitative transmembrane proteins which transport glucose down its concentration gradient. The GLUTs have a tissue specific expression and regulation. Dysregulation of GLUTs have been implicated in the pathogenesis of a number of diseases including diabetes and cancer and are known to play an important role in the developing embryo. In addition, roles for GLUTs in cardiac function and embryonic development have been identified and will be discussed in this review. The ability to ablate or over-express GLUTs has advanced our understanding of the role these transporters play in the maintenance of normal glucose homeostasis and the pathogenesis of diabetes. The development of Cre-LoxP technology coupled with the existence of tissue specific promoters allows investigators to manipulate gene expression both globally and in a tissue specific manner. The major GLUTs which have been investigated using transgenic technology are GLUT1, GLUT4 and GLUT2. Overexpression of GLUT4 and GLUT1 results in increased glucose uptake and metabolism. However, only GLUT4 overexpression protects against the development of insulin resistance in transgenic mice. Genetic ablation of GLUT4 and GLUT2 results in impaired insulin tolerance and defects in both lipid and glucose metabolism. This review will present various transgenic models of GLUT modification and discuss what has been learned from these models about the role that GLUTs play in glucose homeostasis, insulin action and development.

AB - The glucose transporters (GLUTs) are currently a 13 member family of facilitative transmembrane proteins which transport glucose down its concentration gradient. The GLUTs have a tissue specific expression and regulation. Dysregulation of GLUTs have been implicated in the pathogenesis of a number of diseases including diabetes and cancer and are known to play an important role in the developing embryo. In addition, roles for GLUTs in cardiac function and embryonic development have been identified and will be discussed in this review. The ability to ablate or over-express GLUTs has advanced our understanding of the role these transporters play in the maintenance of normal glucose homeostasis and the pathogenesis of diabetes. The development of Cre-LoxP technology coupled with the existence of tissue specific promoters allows investigators to manipulate gene expression both globally and in a tissue specific manner. The major GLUTs which have been investigated using transgenic technology are GLUT1, GLUT4 and GLUT2. Overexpression of GLUT4 and GLUT1 results in increased glucose uptake and metabolism. However, only GLUT4 overexpression protects against the development of insulin resistance in transgenic mice. Genetic ablation of GLUT4 and GLUT2 results in impaired insulin tolerance and defects in both lipid and glucose metabolism. This review will present various transgenic models of GLUT modification and discuss what has been learned from these models about the role that GLUTs play in glucose homeostasis, insulin action and development.

KW - Cardiovascular

KW - Development

KW - Diabetes

KW - GLUT

KW - Hypertrophy

KW - Insulin

KW - Knockout

KW - Transgenic

UR - http://www.scopus.com/inward/record.url?scp=18044389688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044389688&partnerID=8YFLogxK

U2 - 10.2174/1568013053586496

DO - 10.2174/1568013053586496

M3 - Article

AN - SCOPUS:18044389688

VL - 5

SP - 189

EP - 206

JO - Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

JF - Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

SN - 1871-5222

IS - 2

ER -